Company intelligence / Profile preview

BlinkBio

Jupiter, Florida, United Stateszoominfo.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

BlinkBio develops next-generation tunable drug conjugate therapies using proprietary bioorthogonal linker chemistries. Their TDC platform enables rapid payload release in tumors and systemic clearance of the parent drug conjugate. The company has partnered with OS Therapies to apply its technology in osteosarcoma and pediatric cancers. No clinical results have been published by BlinkBio itself as of the latest available data.

Therapeutic areas: OncologyOther
Modalities: Antibody-drug conjugates (ADCs)Tunable drug conjugates (TDCs)Small moleculesPeptide therapeutics
Industry: Biotech

Partnerships

OS Therapies (licensing agreement for ADC/TDC technology applied to osteosarcoma/pediatric cancer)

Beyond the preview

Go deeper on BlinkBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BlinkBio.

Explore the full profile